Receive The Newest Study Notifications

-- 93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response -- -- Findings Support Regulatory Filings for Kite’s Second CAR T Cell Therapy -- -- Data Presented at American Society of Hematology (ASH)...

Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced the initiation of a...

Mark Terry for Biospace writes: It was, as usual, a pretty busy week in clinical trial news. Here’s a look. ASLAN Pharmaceuticals announced positive preliminary data from the lowest dose cohort of its trial of ASLAN004 for moderate-to-severe atopic dermatitis....

CAMBRIDGE, England & MOSCOW--(BUSINESS WIRE)--IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company,...

NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH...

Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today...

88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients 52% of evaluable MDS patients discontinued treatment for stem cell transplant BOSTON, Dec. 09,...

– KVD001 Does Not Meet Primary Endpoint – – Pre-Planned Analyses Show Clinical Benefit on Vision – – KVD001 Generally Safe and Well Tolerated – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...

LAVAL, Quebec — Altasciences has been selected by Indivior PLC to conduct “A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed...

DUBLIN, Ireland & BURLINGAME, Calif.--(BUSINESS WIRE)--ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from the hematological portion of the ALX148 Phase 1 program at...

FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than 50% healing at 3 months vs control wounds Majority of potential...

-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS -- -- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy -- -- Median Duration of Response Not Yet Reached, with...

Neuroimaging shows AMBAR clinical trial’s positive effects in patients with mild-to-moderate Alzheimer’s disease Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, concluded more than a year of encouraging results of...

Celltrion announced on Dec. 9 that it has disclosed its biosimilar Truxima’s results of phase 3 clinical trial at the 2019 annual meeting of the American Society of Hematology last week. “The clinical trials were conducted among patients in European countries...

Ocugen, Inc., (NASDAQ: OCGN) today announced that it has completed 50% of enrollment of its Phase 3 clinical trial for OCU300 for patients with ocular Graft Versus Host Disease (oGVHD). Ocugen is the first and only company to receive Orphan Drug Designation for a...

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc.  (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening...

SYDNEY, Australia I December 05, 2019 I NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of...

SOUTH SAN FRANCISCO, CA, USA I December 05, 2019 I Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s...